<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999999</url>
  </required_header>
  <id_info>
    <org_study_id>Tachousb-1</org_study_id>
    <secondary_id>EKBB 182/09</secondary_id>
    <secondary_id>Swissmedic 2009DR4198</secondary_id>
    <nct_id>NCT00999999</nct_id>
  </id_info>
  <brief_title>Efficacy of Tachosil as Dural Sealant Compared to Standard Treatment</brief_title>
  <official_title>Fleece Bound Tissue Sealing With TachoSil® to Assist in Closing of the Dura Mater After Elective Craniotomy to Reduce Postoperative Cerebrospinal Fluid (CSF) Leakage.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective of this trial is to assess the hypothesis whether the application of TachoSil®&#xD;
      as a dural sealant improves the quality of craniotomy procedure and outcome in general&#xD;
      compared with standard dural closure techniques in a controlled and randomized way. As a&#xD;
      primary endpoint the investigators look at possible postoperative occurrence of CSF pads or&#xD;
      leakages needing any kind of intervention until day 30 after the primary craniotomy.&#xD;
      Furthermore, the investigators will look at other surgery-related complications and at&#xD;
      pharmacoeconomic endpoints such as hospital stay or cost of the implant. Overall, the results&#xD;
      of this study will provide important information on whether or not the adjunct of a&#xD;
      relatively expensive implant on a routinely basis for the closure of elective craniotomies is&#xD;
      safe and effective, or not.&#xD;
&#xD;
      To date, TachoSil® is often used in neurosurgery and other surgical disciplines in a&#xD;
      non-standardized fashion also to prevent CSF leakage after dural closure. So far, adverse&#xD;
      events directly related to the product have not been reported. Theoretically, any implant may&#xD;
      be associated with a higher incidence of postoperative infections (e.g. epidural, subdural or&#xD;
      subgaleal empyema). On the other hand, it is not known whether or not the application of&#xD;
      TachoSil® on the dural suture may reduce CSF leakage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of CSF pad or leakage needing any kind of intervention.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Subjects Scheduled for Supra-/Infratentorial Craniotomy</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dural closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental dural closure, adding of Investigational Medicinal Product (IMP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Craniotomy supra- or infratentorial, dural closure</intervention_name>
    <description>After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neurosurgical indication for craniotomy and opening of dura to access cerebral&#xD;
             structures/pathologies (discussed in the indication conference of board certified&#xD;
             neurosurgeons at the University Hospital of Basel).&#xD;
&#xD;
          -  The list of pathologies includes:&#xD;
&#xD;
               -  primary or secondary benign/malignant brain tumors&#xD;
&#xD;
               -  aneurysms&#xD;
&#xD;
               -  arterious-venous malformations&#xD;
&#xD;
               -  cavernomas&#xD;
&#xD;
               -  pituitary adenomas&#xD;
&#xD;
               -  temporal lobectomy (epilepsy surgery)&#xD;
&#xD;
               -  longterm posttraumatic revisions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of subdural empyema/abscess or any kind of infection affecting/infiltrating&#xD;
             the dura mater&#xD;
&#xD;
          -  Emergency for trauma&#xD;
&#xD;
          -  Previous surgery on the same site&#xD;
&#xD;
          -  Cases, where water-tight dural suture is not possible (intraoperative exclusion&#xD;
             decision)&#xD;
&#xD;
          -  Known hypersensitivity to TachoSil®&#xD;
&#xD;
          -  Participation in another study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to read and understand the participant's information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariani Luigi, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>October 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2009</study_first_posted>
  <last_update_submitted>September 14, 2015</last_update_submitted>
  <last_update_submitted_qc>September 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Craniotomy outcome</keyword>
  <keyword>CSF leakage</keyword>
  <keyword>Dural sealant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

